Logo

GeneGo Licenses MetaCore to Velcura for Three Years

Nov 10, 2005

NEW YORK, Nov. 10 (GenomeWeb News) - GeneGo has has licensed its pathway database and data mining software to Velcura Therapeutics for three years, the companies said today.

 

Velcura plans to use the MetaCore product for gene expression analysis and proteomic analysis in bone-related disease research, the companies said.

 

GeneGo and Velcura did not disclose financial details of the agreement.

Breaking News
The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.